CRISPR Therapeutics Q1 Earnings Predictions Released

On February 14, 2025, analysts from Leerink Partners shared their projections for CRISPR Therapeutics AG's upcoming earnings for the first quarter of 2025. In their report, analyst M. Foroohar anticipates that CRISPR Therapeutics will record earnings per share (EPS) of ($1.33) for the quarter. Currently, the consensus estimate for the full-year earnings stands at ($5.08) per share. Furthermore, the analysts have outlined estimates for the subsequent quarters of 2025, predicting that Q2 earnings will reach ($1.30) EPS, Q3 will be ($1.26) EPS, and Q4 is also expected to be ($1.26) EPS. For the fiscal year 2026, the EPS forecast is ($5.17).

Stock analysis on CRISPR Therapeutics has included varied evaluations. TD Cowen upgraded the stock from a "sell" rating to a "hold" rating with a target price of $35. Meanwhile, Royal Bank of Canada has lowered its price target from $53.00 to $48.00 with a "sector perform" rating. Barclays has made a slight upward adjustment from $55.00 to $56.00 while maintaining an "equal weight" rating. Truist Financial has raised its price target significantly from $100.00 to $120.00 and continues to promote the stock with a "buy" recommendation. On the contrary, Goldman Sachs cut its price target from $66.00 to $57.00, assigning a "neutral" rating. Overall, two analysts have rated the stock as a sell, ten as hold, and eleven as buy, leading to a consensus rating of "Hold" and an average target price of $74.05, according to data from MarketBeat.

Current Stock Performance

As of Thursday, February 14, 2025, CRISPR Therapeutics shares opened at $43.49. The company has experienced significant volatility over the past year, hitting a low of $36.52 and a high of $91.10. With a market capitalization of $3.71 billion, CRISPR Therapeutics currently has a negative PE ratio of -15.37 and a beta of 1.67. The company's 50-day moving average is reported at $42.06, with a 200-day average at $46.25.

Recent Earnings Announcement

CRISPR Therapeutics recently disclosed its quarterly earnings results on February 11, 2025. The company reported a loss of ($0.44) EPS, which surpassed analysts' expectations of ($1.15) by a significant margin of $0.71. The quarter reflected a negative return on equity of 12.15% and a troubling net margin of -118.13%.

Insider Activity

In additional news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics on December 2, for an average price of $55.10, totaling approximately $826,500. This sale reduced Kulkarni’s stake in the company to 181,540 shares, estimated to be valued at around $10 million following the transaction. Corporate insiders now hold about 4.10% of the company’s stock.

Institutional Ownership Trends

Several large investors have adjusted their positions in CRISPR Therapeutics recently. Highline Wealth Partners LLC has acquired a new stake valued at $39,000 in the fourth quarter. Similarly, Western Pacific Wealth Management LP has doubled their stake, now holding 1,000 shares worth $39,000. Other investors including Wilmington Savings Fund Society FSB and Darwin Wealth Management also acquired new positions within the last three quarters. Presently, institutional investors and hedge funds own approximately 69.20% of CRISPR Therapeutics stock.

Company Overview

CRISPR Therapeutics is a gene-editing company devoted to developing innovative gene-based treatments for serious diseases, leveraging its proprietary CRISPR/Cas9 technology. This groundbreaking technology allows for precise editing of genomic DNA and supports a range of therapeutic programs targeting various disease areas, such as hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

CRISPR, earnings, predictions